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Abstract
IMPORTANCE Current approaches to identifying individuals at high risk for opioid overdose target
many patients who are not truly at high risk.
OBJECTIVE To develop and validate a machine-learning algorithm to predict opioid overdose risk
amongMedicare beneficiaries with at least 1 opioid prescription.
DESIGN, SETTING, AND PARTICIPANTS A prognostic study was conducted between September 1,
2017, and December 31, 2018. Participants (n = 560057) included fee-for-service Medicare
beneficiaries without cancer who filled 1 or more opioid prescriptions from January 1, 2011, to
December 31, 2015. Beneficiaries were randomly and equally divided into training, testing, and
validation samples.
EXPOSURES Potential predictors (n = 268), including sociodemographics, health status, patterns
of opioid use, and practitioner-level and regional-level factors, were measured in 3-month windows,
starting 3months before initiating opioids until loss of follow-up or the end of observation.
MAINOUTCOMESANDMEASURES Opioid overdose episodes from inpatient and emergency
department claims were identified. Multivariate logistic regression (MLR), least absolute shrinkage
and selection operator–type regression (LASSO), random forest (RF), gradient boosting machine
(GBM), and deep neural network (DNN) were applied to predict overdose risk in the subsequent 3
months after initiation of treatment with prescription opioids. Prediction performance was assessed
using the C statistic and other metrics (eg, sensitivity, specificity, and number needed to evaluate
[NNE] to identify one overdose). The Youden index was used to identify the optimized threshold of
predicted score that balanced sensitivity and specificity.
RESULTS Beneficiaries in the training (n = 186686), testing (n = 186685), and validation
(n = 186686) samples had similar characteristics (mean [SD] age of 68.0 [14.5] years, and
approximately 63%were female, 82%were white, 35% had disabilities, 41%were dual eligible, and
0.60% had at least 1 overdose episode). In the validation sample, the DNN (C statistic = 0.91; 95%
CI, 0.88-0.93) and GBM (C statistic = 0.90; 95% CI, 0.87-0.94) algorithms outperformed the LASSO
(C statistic = 0.84; 95% CI, 0.80-0.89), RF (C statistic = 0.80; 95% CI, 0.75-0.84), andMLR (C
statistic = 0.75; 95% CI, 0.69-0.80) methods for predicting opioid overdose. At the optimized
sensitivity and specificity, DNN had a sensitivity of 92.3%, specificity of 75.7%, NNE of 542, positive
predictive value of 0.18%, and negative predictive value of 99.9%. The DNN classified patients into
low-risk (76.2% [142 180] of the cohort), medium-risk (18.6% [34 579] of the cohort), and high-risk
(5.2% [9747] of the cohort) subgroups, with only 1 in 10000 in the low-risk subgroup having an
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Key Points
Question Canmachine-learning
approaches predict opioid overdose risk
among fee-for-service Medicare
beneficiaries?
Findings In this prognostic study of the
administrative claims data of 560057
Medicare beneficiaries, the deep neural
network and gradient boostingmachine
models outperformed other methods
for identifying risk, although positive
predictive values were low given the low
prevalence of overdose episodes.
Meaning Machine-learning algorithms
using administrative data appear to be a
valuable and feasible tool for more
accurate identification of opioid
overdose risk.
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Abstract (continued)
overdose episode. More than 90% of overdose episodes occurred in the high-risk andmedium-risk
subgroups, although positive predictive values were low, given the rare overdose outcome.
CONCLUSIONS ANDRELEVANCE Machine-learning algorithms appear to performwell for risk
prediction and stratification of opioid overdose, especially in identifying low-risk subgroups that have
minimal risk of overdose.
JAMA Network Open. 2019;2(3):e190968.
Corrected on July 5, 2019. doi:10.1001/jamanetworkopen.2019.0968
Introduction
In 2016, 11.8 million American individuals reported using prescription opioids nonmedically,1 and an
estimated 115 individuals died each day from opioid overdose.2-4 The annual cost of misuse or abuse
of opioids exceeds $78.5 billion, including the costs of health care, lost productivity, substance abuse
treatment, and the criminal justice system.5
In response, health systems, payers, and policymakers have developed programs to identify and
intervene in individuals at high risk of problematic opioid use and overdose. These programs,
whether outreach calls from casemanagers, prior authorizations, referrals to substance use disorder
specialists, dispensing of naloxone hydrochloride, or enrollment in lock-in programs, can be
expensive to payers and burdensome to patients. The determination of who is at high risk is a factor
in the size and scope of these interventions and the resources expended. Yet, the definition of high
risk is variable, ranging from a high-dose opioid (defined using various cut points) to the number of
pharmacies or prescribers that a patient visits. These criteria, for example, determine howMedicare
beneficiaries are selected into so-called lock-in programs inMedicare, also called the Comprehensive
Addiction and Recovery Act (CARA) drug management programs.6 These programs will soon be
required for all Part D plans.7
These current measures of high risk were derived from studies that used traditional statistical
methods to identify risk factors for overdose rather than predict an individual’s risk.8-31 However,
individual risk factors may not be strong predictors of overdose risk.32 Moreover, traditional
statistical approaches have limited ability to handle nonlinear risk prediction and complex
interactions among predictors. For example, receipt of a high-dose opioid is a well-known overdose
risk factor, but the complex interactions between opioid dose, substance use disorders, mental
health, emergency department visits, prescriber characteristics, and socioeconomic variables may
yield greater predictive power than one factor alone. The few previous studies focused on predicting
opioid overdose (rather than simply identifying risk factors) either had suboptimal prediction
performance24,28,31 or used case-control designs that were unable to measure true overdose
incidence andmay not adequately calibrate algorithms to real data for rare outcomes such as
overdose.22,25,30
Machine learning is an alternative analytic approach to handling complex interactions in large
data, discovering hidden patterns, and generating actionable predictions in clinical settings. In many
cases, machine learning is superior to traditional statistical techniques.33-38 Machine learning has
beenwidely used in activities from fraud detection to genomic studies but, to our knowledge, has not
yet been applied to address the opioid epidemic. Our overall hypothesis was that a machine-
learning algorithmwould perform better in predicting opioid overdose risk comparedwith traditional
statistical approaches.
The objective of this study was to develop and validate a machine-learning algorithm to predict
opioid overdose amongMedicare beneficiaries with at least 1 opioid prescription. Based on the
prediction score, we stratified beneficiaries into subgroups at similar overdose risk to support clinical
decisions and improved targeting of intervention.We choseMedicare because of the high prevalence
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of prescription opioid use and the availability of national claims data and because the program will
require specific interventions targeting individuals at high risk for opioid-associatedmorbidity.6,7
Methods
Design and Sample
This prognostic study was conducted between September 1, 2017, and December 31, 2018. The
University of Arizona Institutional Review Board approved the study. This study followed the
Standards for Reporting of Diagnostic Accuracy (STARD) and the Transparent Reporting of a
Multivariable PredictionModel for Individual Prognosis or Diagnosis (TRIPOD) reporting guidelines.39,40
We included prescription drug andmedical claims for a 5% random sample of Medicare
beneficiaries between January 1, 2011, and December 31, 2015. We identified fee-for-service adult
beneficiaries without cancer who were US residents and received 1 or more opioid prescriptions
during the study period. We excluded beneficiaries who (1) filled only parenteral opioid prescriptions
and/or cough or cold medication prescriptions containing opioids, (2) hadmalignant cancer
diagnoses (eTable 1 in the Supplement), (3) received hospice, (4) ever enrolled in Medicare
Advantage plans (because their health care use in Medicare Advantage may not be observable), or
(5) had their first opioid prescription after October 1, 2015 (eFigure 1 in the Supplement). An index
date was defined as the date of a patient’s first opioid prescription between April 1, 2011, and
September 30, 2015. Once eligible, beneficiaries remained in the cohort, regardless of whether they
continued to receive opioid prescriptions, until they were censored because of death or the end of
observation.
OutcomeVariables: Opioid Overdose
We identified any occurrence of fatal or nonfatal opioid overdose (prescription opioids or other
opioids, including heroin), defined in each 3-month window after the index prescription using the
International Classification of Diseases, Ninth Revision, and International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision (ICD-10), codes for overdose (eTable 2 in the
Supplement) from inpatient or emergency department settings.14,41-44 Overdose was defined with
either an opioid overdose code as the primary diagnosis (80% of identified overdose episodes) or
other drug overdose or substance use disorder code as the primary diagnosis (eTable 3 in the
Supplement) and opioid overdose as the nonprimary diagnosis (20% of identified overdose
episodes), as defined previously.14 Sensitivity analyses using opioid overdose as the primary
diagnosis and capturing any opioid overdose diagnosis code in any position yielded similar results.
Predictor Candidates
We compiled 268 predictor candidates, informed by the literature (eTable 4 in the Supplement).8-31
Patient, practitioner, and regional factors were measured at baseline in the 3 months before the first
opioid prescription fill and in 3-month windows after initiating prescription opioids. We chose a
3-month window in accordance with the literature and to be consistent with the quarterly evaluation
period commonly used by prescription drugmonitoring programs and health plans.13,14,45 In the
primary analysis, we used the variables measured in each 3-month period (eg, the first) to predict
overdose risk in each subsequent 3-month period (eg, the second) (eFigure 2A in the Supplement).
In sensitivity analyses, instead of using a previous 3-month period to predict overdose in the next
period, we included information collected in all of the historical 3-month windows to predict opioid
risk for each 3-month period for each person (eFigure 2B in the Supplement).
The predictor candidates also included a series of variables related to prescription opioid and
relevant medication use: (1) total and mean daily morphine milligram equivalent (MME),17 (2)
cumulative and continuous duration of opioid use (ie, no gap >32 days between fills),45 (3) total
number of opioid prescriptions overall and by active ingredient, (4) type of opioid based on the US
Drug Enforcement Administration’s Controlled Substance Schedule (I-IV) and duration of action, (5)
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number of opioid prescribers, (6) number of pharmacies providing opioid prescriptions,11,17,23 (7)
number of early opioid prescription refills (refilling opioid prescriptions >3 days before the previous
prescription runs out),46 (8) cumulative days of early opioid prescription refills, (9) cumulative days
of concurrent benzodiazepines and/or muscle relaxant use, (10) number and duration of other
relevant prescriptions (eg, gabapentinoids), and (11) receipt of methadone hydrochloride or
buprenorphine hydrochloride for opioid use disorder.19,47-50
Patient sociodemographic characteristics included age, sex, race/ethnicity, disability as the
reason for Medicare eligibility, receipt of low-income subsidy, and urbanicity of county of residence.
Health status factors (eg, number of emergency department visits) were derived from the literature
and are listed in eTable 4 in the Supplement.13,16,51-54 Practitioner factors included opioid prescriber’s
sex, specialty, meanmonthly opioid prescribing volume andMME, andmeanmonthly number of
patients receiving opioids. Many beneficiaries had more than 1 opioid prescriber, in which case the
practitioner prescribing the highest number of opioids was designated as the primary prescriber.
Regional factors (eg, percentage of households below the federal poverty level) included variables
obtained from publicly available resources, including the Area Health Resources Files, Area
Deprivation Index data sets,55 and County Health Rankings data.56
Machine-Learning Approaches and Prediction Performance Evaluation
Our primary goal was risk prediction, and the secondary goal was risk stratification (ie, identifying
patient subgroups at similar overdose risk). First, we randomly and equally divided the cohort into
training (developing algorithms), testing (refining algorithms), and validation (evaluating algorithm’s
prediction performance) samples. In both the primary and sensitivity analyses (eFigure 2 in the
Supplement), we developed and tested prediction algorithms for opioid overdose using 5 commonly
usedmachine-learning approaches: multivariate logistic regression, least absolute shrinkage and
selection operator–type regression (LASSO), random forest (RF), gradient boosting machine (GBM),
and deep neural network (DNN). Previous studies consistently showed that thesemethods yield the
best prediction results57,58; the eAppendix in the Supplement describes the details for each approach
used. Given that beneficiaries may have multiple opioid overdose episodes, we present the results
from a patient-level random subset (ie, using one 3-month period with predictor candidates
measured to predict risk in the subsequent 3 months for each patient) from the validation data for
ease of interpretation. Episode-level performance was the same as the patient-level results.
To assess discrimination performance (ie, the extent to which patients who were predicted to
be high risk exhibited higher overdose rates comparedwith thosewhowere predicted to be low risk),
we compared the C statistic (or area under the receiver operating curve) and precision-recall curves59
across different methods from the validation sample using the DeLong Test.60 Given that overdose
events are rare outcomes and C statistics do not incorporate information about outcome prevalence,
we reported othermetrics, including sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), positive likelihood ratio, negative likelihood ratio, number needed to evaluate
(NNE) to identify 1 overdose episode, and estimated rate of alerts, to thoroughly assess the
algorithms’ prediction ability (eFigure 3 in the Supplement).61,62 To compare performance across
methods, we presented and assessed thesemetrics at the optimized prediction threshold that
balances sensitivity and specificity, as identified by the Youden index.63 Furthermore, because no
single threshold is suitable for every purpose, we also presented thesemetrics at multiple other
levels of sensitivity and specificity (eg, arbitrarily choosing 90% sensitivity) to enable risk-benefit
evaluations of potential interventions that use different thresholds defining high risk.
On the basis of the distribution of individuals’ estimated probability of an overdose event, we
classified beneficiaries in the validation sample into low risk (predicted score below the optimized
threshold), medium risk (score between the optimized threshold and top fifth percentile), or high
risk (the top fifth percentile of scores, chosen according to clinical utility). We evaluated calibration
plots (the extent to which the predicted overdose risk agreed with the observed risk) by the 3
risk groups.
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To ensure clinical utility, we reported the predictors with the strongest effect. Because no
standardizedmethods exist to identify individual important predictors from the DNNmodel, we
reported the top 50 important predictors from the GBM and RFmodels. We also compared our
prediction performance over a 12-month period with any of the 2019 Centers for Medicare &
Medicaid Services opioid safety measures, which are meant to identify high-risk individuals or
utilization behavior in Medicare.64 These simpler decisionmetrics were constructed from factors
identified from previous studies using traditional approaches (eg, multivariate logistic regression).
Thesemeasures included 3metrics: (1) high-dose use, defined as higher than 120MME for 90 or
more continuous days; (2) 4 or more opioid prescribers and 4 or more pharmacies; and (3)
concurrent opioid and benzodiazepine use for 30 or more cumulative days. In addition to using 3-
and 12-month windows, we conducted a sensitivity analysis using a 6-month window in DNN to
examine whether the prediction quality changes with different time horizons.65
Statistical Analysis
We compared the patient characteristics by overdose status and by training, testing, and validation
sample with unpaired, 2-tailed t test, χ2 test and analysis of variance, or corresponding
nonparametric tests, as appropriate. We assessed correlations between 2 variables using Pearson
correlation coefficient (r). Statistical significance was defined as 2-tailed P < .05.
All analyses were performed using SAS, version 9.4 (SAS Institute Inc); Python, version 3.6
(Python Software Foundation); and Salford Predictive Modeler software suite, version 8.2
(Salford System).
Results
Patient Characteristics
Beneficiaries in the training (n = 186686), testing (n = 186685), and validation (n = 186686)
samples had similar characteristics and outcome distributions (approximately 63%were female,
82%werewhite, 35%had disabilities, and 41%were dual eligible; themean [SD] age was 68.0 [14.5]
years (eTable 5 in the Supplement). Overall, 3188 beneficiaries (0.6%) had at least 1 opioid overdose
episode during the study period.
Prediction Performance ofMachine-Learning Algorithms
Figure 1 summarizes 4 prediction performancemeasures of eachmodel. The DNN (C statistic = 0.91;
95% CI, 0.88-0.93) and GBM (C statistic = 0.90; 95% CI, 0.87-0.94) algorithms outperformed the
LASSO (C statistic = 0.84; 95% CI, 0.80-0.89), RF (C statistic = 0.80; 95% CI, 0.75-0.84), and
multivariate logistic regression (C statistic = 0.75; 95% CI, 0.69-0.80) methods for predicting opioid
overdose (P < .001). In addition, DNN and GBM had similar prediction performance, and DNN had
the best precision-recall performance (Figure 1B), based on an area under the curve of 0.036.
Sensitivity analyses including all the historical 3-month windows yielded similar results (eFigure 4 in
the Supplement).
eTable 6 in the Supplement shows the prediction performancemeasures across different levels
(90%-100%) of sensitivity and specificity for eachmethod. At the optimized sensitivity and
specificity, as measured by the Youden index, GBM had a sensitivity of 86.8%, specificity of 81.1%,
PPV of 0.22%, NPV of 99.9%, NNE of 447, and 24 positive alerts per 100 beneficiaries. Similarly, at
the optimized sensitivity and specificity, DNN had a sensitivity of 92.3%, specificity of 75.7%, PPV of
0.18%, NPV of 99.9%, NNE of 542, and 22 positive alerts per 100 beneficiaries (Figure 1C and D;
eTable 6 in the Supplement). If sensitivity were instead set at 90% (ie, attempting to identify 90%
of individuals with actual overdose episodes), GBM had a specificity of 72.3%, PPV of 0.16%, NPV of
99.9%, NNE of 631 to identify 1 overdose, and 28 positive alerts generated per 100 beneficiaries;
DNN had a specificity of 77.0%, PPV of 0.19%, NPV of 99.9%, NNE of 525, and 23 positive alerts per
100 beneficiaries (eTable 6 in the Supplement). If specificity were set at 90% (ie, identifying 90%
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of individuals with actual nonoverdose), GBM had a sensitivity of 74.7%, PPV of 0.41%, NPV of
99.9%, NNE of 245, and 9 positive alerts per 100 beneficiaries; DNN had a sensitivity of 70.3%, PPV
of 0.34%, and NPV of 99.9%, NNE of 294, and 10 positive alerts per 100 beneficiaries. Overall,
DNN’s prediction scores were highly correlated with the GBM’s prediction scores (r=0.73 for all
patients, 0.73 for those without overdose episodes, 0.80 for those with overdose episodes;
eFigure 5 in the Supplement).
Risk Stratification Using Predicted Probability
Using the GBM algorithm, 144 860 (77.6%) of the sample were categorized into low risk, 32 415
(17.4%) into medium risk, and 9411 (5.0%) into high risk for overdose (Table 1). Among all 91
beneficiaries with an overdose episode in the sample, 54 (59.3%) were captured in the high-risk
group. Similarly, using the DNN algorithm, 9747 individuals (5.2%) were predicted to be high risk,
capturing 56 overdose episodes (61.5%). Among the 142 180 individuals (76.2%) categorized as low
risk, 99.99% did not have an overdose. Figure 2 depicts the actual overdose rate for individuals in
Figure 1. PerformanceMatrix ofMachine-LearningModels for Predicting Opioid Overdose inMedicare Beneficiaries
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Number needed to evaluateC Alerts by 100 patientsD
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The 4 prediction performancematrixes in the validation sample are the area under the
receiver operating characteristic curve (AUC) or C statistic (A); the precision-recall
curves, which have improved performance if they are closer to the upper right corner or
above the othermethod (B); the number needed to evaluate (NNE) by different cutoffs
of sensitivity (C); and alerts per 100 patients by different cutoffs of sensitivity (D).
DNN indicates deep neural network; GBM, gradient boosting machine; LASSO, least
absolute shrinkage and selection operator–type regularized regression; MLR,
multivariate logistic regression; and RF, random forest.
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each of the 3 risk groups. Across both the GBM and DNNmodels, those in the high-risk group had 7
to 8 times the risk of overdose comparedwith those in the lower-risk groups (observed overdose rate
of GBM: 0.57% [high risk], 0.08% [medium risk], and 0.01% [low risk]; observed overdose rate of
DNN: 0.57% [high risk], 0.07% [medium risk], and 0.01% [low risk]). Again, depicted is the negligible
rate of overdose in the low-risk subgroups, representing more than three-quarters of the sample.
Figure 3 shows the most important predictors (n = 50) identified by the GBMmodel, such as
total MME, history of any substance use disorder, mean daily MME, age, and Medicare disability
status. eFigure 6 in the Supplement shows themost important predictors (n = 50) identified by the
RFmodel.
Table 1. Prediction Performance of Gradient BoostingMachine and Deep Neural NetworkModels in the Validation Sample Divided Into Risk Subgroupsa
Performance Metric
GBM DNN
Low Risk Medium Risk High Risk Low Risk Medium Risk High Risk
Total, No. (%) 144 860 (77.6) 32 415 (17.4) 9411 (5.0) 142 180 (76.2) 34 759 (18.6) 9747 (5.2)
Predicted score, median (range)b 14.6 (1.4-39.0) 55.4 (39.0-77.7) 83.8 (77.7-93.8) 14.2 (2.1-46.5) 61.6 (46.5-81.9) 88.7 (81.9-99.7)
No. of actual overdose episodes
(% of each subgroup)
11 (0.01) 26 (0.08) 54 (0.57) 9 (0.01) 26 (0.07) 56 (0.57)
No. of actual nonoverdose episodes
(% of each subgroup)
144 849 (99.99) 32 389 (99.92) 9357 (99.43) 142 171 (99.99) 34 733 (99.93) 9691 (99.43)
Sensitivity, % 0 100 100 0 100 100
PPV, %c NA 0.08 0.57 NA 0.07 0.57
NNEc NA 1247 174 NA 1337 174
Specificity, % 100 0 0 100 0 0
NPV, %c 99.99 NA NA 99.99 NA NA
Overall No. of misclassified overdose episodes
(% of overall cohort)c
11 (0.006) 32 389 (17.4) 9357 (5.0) 9 (0.005) 34 733 (18.6) 9691 (5.2)
% of All overdose episodes captured over 3 mo
(n = 91)
12.1 29.6 59.3 9.9 28.6 61.5
Abbreviations: DNN, deep neural network; GBM, gradient boosting machine; NA, not
able to be calculated owing to 0 denominator; NNE, number needed to evaluate; NPV,
negative predictive value; PPV, positive predictive value.
a Risk subgroups were classified into low risk (score below the optimized threshold),
medium risk (predicted score between the optimized threshold and the top fifth
percentile score), and high risk (predicted score in the top fifth percentile). The
optimized thresholds were 39 (or probability of 0.39) for GBM and 46.5 (or probability
of 0.465) for DNN.
b Predicted scores were calculated by the predicted probability of overdosemultiplied
by 100.
c If classifying medium- and high-risk groups as overdose and low-risk group as
nonoverdose, then the PPV and NNEwere not able to be calculated for the low-risk
group because this group was considered as nonoverdose. Similarly, the NPVwas not
able to calculate for the medium- and high-risk groups because these groups were
considered as overdose. Detailed definitions of prediction performancemetrics are
provided in eFigure 3 in the Supplement.
Figure 2. Calibration Performance of Gradient BoostingMachine (GBM) and DeepNeural Network (DNN)
by Risk Group
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Risk subgroups were classified into 3 groups using the
optimized threshold in the validation sample
(n = 186686): low risk (score below the optimized
threshold), medium risk (predicted score between the
optimized threshold, identified by the Youden index,
and the top fifth percentile score), and high risk
(predicted score in the top fifth percentile). The
dashed line indicates the overall observed overdose
rate without risk stratifications.
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Table 2 compares the performance of the DNN algorithmmeasures with the Centers for
Medicare &Medicaid Services opioid safety measures. By targeting the high-risk group, DNN’s
algorithm captured approximately 90%of 297 individuals with actual overdose episodes (NNE = 56)
in a 12-month period, with 14 917 (8.9%) of the overall cohort beingmisclassified as having overdose,
whereas the Centers for Medicare & Medicaid Services measures captured 30% of 297 individuals
actual overdose episodes (NNE = 108), with 5.51% of the overall cohort being misclassified as
overdose. The GBM and DNN algorithms performed similarly (eTable 7 in the Supplement).
Sensitivity analyses using 6-month windows yielded similar C statistic with an improved PPV
compared with using 3-month windows (eg, C statistic = 0.89; 95% CI, 0.87-0.90; PPV = 0.36%
in DNN).
Figure 3. Top 50 Important Predictors for Opioid Overdose Selected by Gradient BoostingMachine
Total MME
History of any SUD/AUD
Average daily MME
Age
Disability status
No. opioid fills
Beneficiaries’ resided state
Type of opioid
No. benzodiazepine fills
Cumulative days of early refills
Drug use disorders
Rural vs urban areas
Receiving low-income subsidy
Mood disorders
Average No. monthly nonopioid prescriptions
Cumulative days of gabapentinoid use
Anxiety disorders
Falls, fractures, and other injuries
Psychoses
Area-level percentage of mammography screening
Area-level percentage of violence/crime
Area-level percentage of unemployment
Area-level percentage of physical inactivity
Days from last overdose event
Area-level hospital readmission rate (FFS Medicare)
Area-level preventive hospital stay rate (FFS Medicare)
Area-level homicide rate
Area-level percentage of not proficient in English
Preventable hospital rate
Having urine drug test
Area-level percentage of children in poverty
Area-level No. ED visits per 1000 FFS Medicare beneficiaries 
Area-level percentage of excessive drinking
Area-level Medicare advantage penetration %
Area-level teen birth rate
Race
Area-level No. mental health providers
Days of concurrent opioid and benzodiazepine use
Area-level HIV rate
Area-level percentage of poor to fair health
Area-level percentage of women in FFS Medicare
Area-level vehicle/crash-related deaths rate
Area-level mentally unhealthy days
Cumulative days of short-acting opioid use
Area-level percentage of individuals aged 18-64 without health insurance
Area-level No. disabled enrolled
Area-level low birth weight percentage
Continuous duration of long-acting opioid use
Area-level sexual transmission infection rate
No. antidepressant fills
0 20 40 60 80 100
Importance Factor, %
Rather than P values or coefficients, the gradient
boosting machine reports the importance of
predictors included in a model. Importance is a
measure of each variable’s cumulative contribution
toward reducing square error, or heterogeneity within
the subset, after the data set is sequentially split
according to that variable. Thus, importance reflects a
variable’s significance in prediction. Absolute
importance is then scaled to give relative importance,
with amaximum importance of 100. For example, the
top 10 important predictors identified from the
gradient boostingmachinemodel included total opioid
dose (eg, >1500morphinemilligram equivalent [MME]
during 3months), diagnosis of alcohol use disorders
or substance use disorders (AUD/SUD), mean daily
opioid dose (eg, >32MME), age, disability status, total
number of opioid prescriptions (eg, >4), beneficiary’s
state residency (eg, Florida, Kentucky, or New Jersey),
type of opioid use (eg, with mixed schedules), total
number of benzodiazepine prescription fills (eg, >3),
and cumulative days of early prescription refills (eg,
>19 days). ED indicates emergency department; FFS:
fee-for-service.
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Discussion
Using national Medicare data, we developedmachine-learning models with strong performance for
predicting opioid overdose. The GBM and DNNmodels achieved high C statistic (>0.90) for
predicting overdose risk in the subsequent 3 months after initiation of treatment with prescription
opioids and outperformed traditional classification techniques. As expected in a populationwith very
low prevalence of the outcome, the PPV of themodels was low; however, these algorithms
effectively segmented the population into 3 risk groups according to predicted risk score, with three-
quarters of the sample in a low-risk group with a negligible overdose rate andmore than 90% of
individuals with overdose captured in the high- andmedium-risk groups. The ability to identify such
risk groups has important potential for policymakers and payers who currently target interventions
based on less accurate measures to identify patients at high risk.
We identified 7 previously published studies of opioid predictionmodels, each focused on
predicting a different aspect of opioid use disorder and not applying advancedmachine learning. The
studies predicted a 12-month risk of opioid use disorder diagnosis using private insurance claims13,22;
2-year risk of clinical, electronic medical record–documented problematic opioid use in a primary
care setting24; 12-month risk of overdose or suicide-associated events using data from the Veterans
Health Administration 31; 6-month risk of serious prescription opioid–induced respiratory depression
or overdose using data from the Veterans Health Administration and claims data from Insurance
Management Services private insurance25,30; and 2-year risk of fatal or nonfatal overdose using
electronic medical record data.28 These studies had several key limitations, including use of case-
control designs unable to calibrate to population-level data with the true incidence rate of overdose;
measuring predictors at baseline rather than over time; capturing only the first overdose episode;
inability to identify complex or nonintuitive relationships (interactions) between the predictors and
outcomes; and having suboptimal prediction performance (with a C statistic of up to 0.72 in
Table 2. Comparison of Prediction Performance Between Centers forMedicare &Medicaid ServicesMeasures and Deep Neural NetworkMeasures
Over a 12-Month Period
Performance Metric
DNN Measuresa CMS Opioid Safety Measuresb
Low Risk Medium Risk High Risk Low- or No-Risk Opioid Use High-Risk Opioid Use
Total, No. (%) 112 548 (67.5) 38 846 (23.3) 15 186 (9.1) 157 299 (94.4) 9281 (5.5)
Predicted score, median (range) 14.0 (2.1-46.5) 62.8 (46.5-81.9) 88.1 (81.9-99.7) NA NA
No. of actual overdose episodes
(% of each subgroup)
7 (0.006) 21 (0.05) 269 (1.77) 210 (0.13) 87 (0.93)
No. of actual nonoverdose episodes
(% of each subgroup)
112 541 (99.99) 38 825 (99.94) 14 917 (98.22) 157 089 (99.86) 9194 (99.06)
Sensitivity, % 0 100 100 0 100
PPV, % NA 0.05 1.77 NA 0.93
NNE NA 2000 56 NA 108
Specificity, % 100 0 0 100 0
NPV, % 99.99 NA NA 99.86 NA
Overall No. of misclassified overdose episodes
(% of overall cohort)c
7 (0.004) 38 825 (23.3) 14 917 (8.95) 210 (0.12) 9194 (5.51)
% of all overdose episodes captured over 12 mo
(n = 297)
2.35 7.07 90.57 70.7 29.29
Abbreviations: CMS, Centers for Medicare &Medicaid Services; DNN, deep neural
network; NA, not able to calculate; NNE, number needed to evaluate; NPV, negative
predictive value; PPV, positive predictive value.
a In contrast to Table 1, themeasures were defined according to a 12-month period rather
than a 3-month period. The sample size was smaller than in themain analysis because
it required people to have at least 12 months of follow-up.
b The 2019 CMS opioid safety measures are meant to identify high-risk individuals or
utilization behavior.64 Thesemeasures include 3metrics: (1) high-dose use, defined as
higher than 120morphinemilligram equivalent (MME) for 90 ormore continuous days,
(2) 4 or more opioid prescribers and 4 or more pharmacies, and (3) concurrent opioid
and benzodiazepine use for 30 or more days.
c If classifying medium- and high-risk groups as overdose for DNN and low-risk group as
nonoverdose, then individuals with actual nonoverdose in these 2 groups were
misclassified. If classifying those with any of CMS high-risk opioid usemeasures as
overdose, and the remaining group considered as nonoverdose, then individuals with
actual nonoverdose in the high-risk groups were misclassified. The PPV and NNE were
not able to calculate for the low-risk group because this group was considered as
nonoverdose. Similarly, the NPV was not able to calculate for the medium- and high-
risk groups because these groups were considered as overdose. Detailed definitions of
prediction performancemetrics are provided in eFigure 3 in the Supplement.
JAMANetworkOpen | SubstanceUse andAddiction Machine-Learning Algorithms for Predicting Opioid Overdose Risk AmongMedicare Beneficiaries
JAMA Network Open. 2019;2(3):e190968. doi:10.1001/jamanetworkopen.2019.0968 (Reprinted) March 22, 2019 9/15
Downloaded From: https://jamanetwork.com/ by a University of Arizona Health Sciences Library User  on 08/19/2019
non–case-control designs). The present study overcomes these limitations using a population-based
sample andmachine-learningmethods. To our knowledge, this study is the first to predict overdose
risk in the subsequent 3-month period after initiation of treatment with prescription opioids as
opposed to 1-year or longer period.
The extant literature in predicting health outcomes often focuses on C statistics rather than the
full spectrum of prediction performance. This study found high C statistics (>0.90) frommachine-
learning approaches. However, although opioid overdose represents a particularly important
outcome, it is a rare outcome, especially in theMedicare population. Relying on C statistics alonemay
lead to overestimating the advantages of a prediction tool or underestimating the costs of clinical
resources involved. For a preimplementation evaluation of a clinical prediction tool, it is
recommended that researchers report sensitivity and at least 1 other metric (eg, PPV, NNE, or
estimated alert rate) to present a more complete picture of the performance characteristics of a
specific model.59,61 In this study, the NNE value using DNN and GBM algorithms is similar to other
commonly used cancer screening tests, such as annual mammography to prevent 1 breast cancer
death (NNE = 233-1316, varying by subgroups with different underlying risk).66
Unlike sensitivity and specificity, which are properties of the test alone, the PPV and NPV are
affected by the prevalence of the outcome in the population tested. Low outcome prevalence leads
to low PPV and high NPV, even in tests with high sensitivity and specificity, and could limit the clinical
utility of a prediction algorithm such as ours because of false-positives. Other tests with good
discrimination have low PPV because of overall prevalence, including trisomy 21 screening in 20- to
30-year-old women (prevalence of approximately 1:1200),67 with a PPV of 1.7% at a test with
sensitivity higher than 99% and specificity higher than 95%. Despite the low PPV in this study, our
risk stratification strategies may more efficiently guide the targeting of opioid interventions among
Medicare beneficiaries compared with exisiting measures. This strategy first excludes most
(approximately 75%) prescription opioid users with negligible overdose risk from burdensome
interventions like pharmacy lock-in programs and specialty referrals. Targetingmedium- and/or high-
risk groups can capture nearly all (90%) overdose episodes by focusing on only 25% of the
population, which greatly frees up resources for payers and patients. For those in the high- and
medium-risk groups, althoughmost will be false-positives for overdose given the overall low
prevalence, additional screening and assessment may be warranted. Although certainly not perfect,
thesemachine-learningmodels allow interventions to be targeted to the small number of individuals
who are at greater risk, and these models are more useful than other prediction criteria that have
considerably more false-positives.
Limitations
The study has important limitations. First, patients may obtain opioids from nonmedical settings,
which are not captured in claims data. Second, this study captured overdose episodes in medical
settings andmissed overdose episodes that occurred outside of medical settings, which are not
captured in claims data. Third, the study relied on administrative billing data that lacked laboratory
results and sociobehavioral information. This limitation can be addressed in the future with more
robust linked data. In addition, although the study was novel in measuring overdose risk in the
subsequent 3 months after initiation of prescription opioids, it used older data with complete claims
capture; translation into real-time risk scores can be complicated by the lag in claims completion
after the time of visit. Fourth, our focus was on predicting opioid overdose, and not opioid misuse,
which is difficult tomeasure solely from claims data. Fifth, prediction algorithms and findings derived
from the fee-for-service Medicare populationmay not generalize to individuals enrolled in Medicare
Advantage plans or to other populations with different demographic profiles or programmatic
features. However, the models may have better prediction performance in settings in which
overdose is less rare (eg, Medicaid).
JAMANetworkOpen | SubstanceUse andAddiction Machine-Learning Algorithms for Predicting Opioid Overdose Risk AmongMedicare Beneficiaries
JAMA Network Open. 2019;2(3):e190968. doi:10.1001/jamanetworkopen.2019.0968 (Reprinted) March 22, 2019 10/15
Downloaded From: https://jamanetwork.com/ by a University of Arizona Health Sciences Library User  on 08/19/2019
Conclusions
This study demonstrates the feasibility and potential of machine-learning predictionmodels with
routine administrative claims data available to payers. Thesemodels have high C statistics and good
prediction performance and appear to be valuable tools for more accurately and efficiently
identifying individuals at high risk of opioid overdose.
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